Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cetuximab with Paclitaxel and Carboplatin in Advanced Ovarian Cancer
NCT00063401Phase 2Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2003
- Primary completion
- Jun 2006
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cetuximab in ovarian cancer, primary peritoneal cancer (PPC) and fallopian tube cancer (PFTC), sponsored by Eli Lilly and Company. Primary endpoint: Progression-Free Survival. Started Sep 2003; status: completed.
02
Drugs
cetuximab
03
Conditions
ovarian cancerprimary peritoneal cancer (PPC)fallopian tube cancer (PFTC)
Beyond the preview
Go deeper on NCT00063401.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00063401.